S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
My No. 1 dividend stock for a LIFETIME of income. (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
My No. 1 dividend stock for a LIFETIME of income. (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
My No. 1 dividend stock for a LIFETIME of income. (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Can Carnival Cruise Lines Set Sail For New Highs? 
BioNTech Is Ripe For A Rebound In 2023 
My No. 1 dividend stock for a LIFETIME of income. (Ad)
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Finland's NATO membership: What's next?
Will Investors Lose Their Shirts Chasing Gap's 6.8% Dividend?
NASDAQ:LXRX

Lexicon Pharmaceuticals - LXRX Stock Forecast, Price & News

$2.31
-0.01 (-0.43%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.29
▼
$2.38
50-Day Range
$2.17
▼
$2.68
52-Week Range
$1.31
▼
$3.48
Volume
289,635 shs
Average Volume
530,014 shs
Market Capitalization
$435.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50

Lexicon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
376.2% Upside
$11.00 Price Target
Short Interest
Bearish
2.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.57) to ($0.27) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

569th out of 995 stocks

Pharmaceutical Preparations Industry

270th out of 482 stocks

See Top Rated MarketRank™ Stocks Here

LXRX stock logo

About Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Stock News Headlines

March 8, 2023 | msn.com
Lexicon Pharmaceuticals's Return On Capital Employed Insights
March 8, 2023 | msn.com
Jefferies Initiates Coverage of Lexicon Pharmaceuticals (LXRX) with Hold Recommendation
March 28, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
March 7, 2023 | msn.com
Lexicon initiated at buy at Jefferies on uptake of heart failure candidate sotagliflozin
March 4, 2023 | finance.yahoo.com
Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization
March 4, 2023 | finance.yahoo.com
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology
March 3, 2023 | marketwatch.com
Lexicon Pharmaceuticals Stock Jumps on 4Q Revenue, Sotagliflozin Heart Drug Update
March 2, 2023 | msn.com
Lexicon Pharmaceuticals GAAP EPS of -$0.16 misses by $0.03, revenue of $0.03M misses by $0.02M
March 28, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
March 2, 2023 | finance.yahoo.com
Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
March 1, 2023 | msn.com
Earnings Preview For Lexicon Pharmaceuticals
March 1, 2023 | finance.yahoo.com
Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023
February 22, 2023 | thestreet.com
Lexicon Shares Soar After Success in Late-Stage Cancer Drug Trial
February 20, 2023 | finance.yahoo.com
New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology
February 1, 2023 | finance.yahoo.com
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders are private equity firms with 48% ownership, institutions own 26%
January 6, 2023 | finance.yahoo.com
Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
December 22, 2022 | finance.yahoo.com
Lexicon Pharma's Pain Candidate Fails In Postherpetic Neuralgia Study
December 21, 2022 | marketwatch.com
Lexicon Pharmaceuticals Shares Drop 11% on LX9211 Study Results
December 21, 2022 | finance.yahoo.com
Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
December 14, 2022 | msn.com
Lexicon Pharmaceuticals's Return On Capital Employed Overview
November 28, 2022 | finance.yahoo.com
Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference
November 15, 2022 | finance.yahoo.com
Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit
November 12, 2022 | finance.yahoo.com
Lexicon Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
November 11, 2022 | finance.yahoo.com
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
November 10, 2022 | markets.businessinsider.com
Lexicon Pharmaceuticals (LXRX) Gets a Hold from Needham
November 10, 2022 | seekingalpha.com
Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Call Transcript
November 9, 2022 | finance.yahoo.com
Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
See More Headlines
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Company Calendar

Last Earnings
11/03/2021
Today
3/28/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CUSIP
52887210
CIK
1062822
Web
www.lexpharma.com
Phone
(281) 863-3000
Fax
281-863-8010
Employees
87
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+181.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-101,940,000.00
Net Margins
-73,341.00%
Pretax Margin
-73,341.01%
Return on Equity
-96.02%
Return on Assets
-64.27%

Debt

Debt-to-Equity Ratio
0.41
Current Ratio
6.08
Quick Ratio
6.08

Sales & Book Value

Annual Sales
$140,000.00
Price / Sales
3,114.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.62 per share
Price / Book
3.73

Miscellaneous

Outstanding Shares
188,730,000
Free Float
176,459,000
Market Cap
$435.97 million
Optionable
Optionable
Beta
1.32

Social Links


Key Executives

  • Lonnel Coats
    Chief Executive Officer & Director
  • Jeffrey L. Wade
    President & Chief Financial Officer
  • Craig B. Granowitz
    Chief Medical Officer & Senior Vice President
  • Brian T. Crum
    Secretary, Senior Vice President & General Counsel
  • Kiernan A. Seth
    Chief Commercial Officer & Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













LXRX Stock - Frequently Asked Questions

Should I buy or sell Lexicon Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LXRX shares.
View LXRX analyst ratings or view top-rated stocks.

What is Lexicon Pharmaceuticals' stock price forecast for 2023?

3 Wall Street research analysts have issued 1 year price targets for Lexicon Pharmaceuticals' stock. Their LXRX share price forecasts range from $3.00 to $20.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 376.2% from the stock's current price.
View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts.

How have LXRX shares performed in 2023?

Lexicon Pharmaceuticals' stock was trading at $1.91 at the beginning of the year. Since then, LXRX shares have increased by 20.9% and is now trading at $2.31.
View the best growth stocks for 2023 here.

When is Lexicon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our LXRX earnings forecast.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The biopharmaceutical company had revenue of $0.02 million for the quarter. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 96.02% and a negative net margin of 73,341.00%. During the same quarter in the previous year, the firm earned $0.71 earnings per share.

What ETFs hold Lexicon Pharmaceuticals' stock?

ETFs with the largest weight of Lexicon Pharmaceuticals (NASDAQ:LXRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB) and

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (1.74%), Pinnacle Associates Ltd. (1.05%), Pinnacle Associates Ltd. (1.02%), Geode Capital Management LLC (0.85%), Point72 Asset Management L.P. (0.71%) and Millennium Management LLC (0.62%). Insiders that own company stock include International SCA Artal and James F Tessmer.
View institutional ownership trends.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $2.31.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $435.97 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-101,940,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.

This page (NASDAQ:LXRX) was last updated on 3/28/2023 by MarketBeat.com Staff